Final analysis COMET-2: Cabozantinib (Cabo) versus mitoxantrone/prednisone (MP) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with moderate to severe pain who were previously treated with docetaxel(D) and abiraterone (A) and/or enzalutamide (E) Meeting Abstract


Authors: Basch, E. M.; Sholz, M. C.; de Bono, J. S.; Vogelzang, N. J.; De Souza, P. L.; Marx, G. M.; Vaishampayan, U. N.; George, S.; Schwarz, J. K.; Antonarakis, E. S.; O'Sullivan, J. M.; Kelabasty, A. R.; Chi, K. N.; Dreicer, R.; Hutson, T. E.; Mangeshkar, M.; Holland, J. S.; Weitzman, A.; Scher, H. I.
Abstract Title: Final analysis COMET-2: Cabozantinib (Cabo) versus mitoxantrone/prednisone (MP) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with moderate to severe pain who were previously treated with docetaxel(D) and abiraterone (A) and/or enzalutamide (E)
Meeting Title: 2015 Genitourinary Cancers Symposium
Journal Title: Journal of Clinical Oncology
Volume: 33
Issue: 7 Suppl.
Meeting Dates: 2015 Feb 26-28
Meeting Location: Orlando, FL
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2015-03-01
Language: English
ACCESSION: WOS:000356886700143
PROVIDER: wos
Notes: Meeting Abstract: 141 -- Source: Wos
MSK Authors
  1. Ethan Martin Basch
    152 Basch
  2. Howard Scher
    792 Scher